Ligand Pharmaceuticals Incorporated ( LGND) - Key Metrics
LGND Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q1 | ? | ? | ? | ? |
| 2025Q4 | $3.02 | $2.27 | $2.32 | $2.32 |
| 2025Q3 | $5.96 | $6.06 | $0.68 | $0.68 |
| 2025Q2 | $2.46 | $0.25 | $0.82 | $0.81 |
| 2025Q1 | $2.36 | -$2.21 | -$1.33 | -$1.34 |
LGND Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q1 | ? | ? |
| 2025Q4 | ? | 20.82 |
| 2025Q3 | ? | 7.31 |
| 2025Q2 | ? | 113.32 |
| 2025Q1 | ? | -11.88 |
LGND Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q1 | 1.22% | ? |
| 2025Q4 | 1.23% | ? |
| 2025Q3 | 0.38% | ? |
| 2025Q2 | 0.71% | ? |
| 2025Q1 | -1.28% | ? |
LGND
Price: $253.25
52 week price:
Payout Ratio Range:
Earnings Per Share: 7.67 USD
P/E Ratio: 27.09
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 186100
Ebitda: 19.2 millionMarket Capitalization: 4.7 billion